J. Chmielecki

发表

Anchored multiplex PCR for targeted next-generation sequencing

A. Iafrate, W. Pao, J. Engelman, 2014, Nature Medicine.

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

Adrian V. Lee, P. Lucas, S. Oesterreich, 2017, JAMA oncology.

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies

W. Pao, D. Fabrizio, J. Chmielecki, 2017, Genome Medicine.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Levi Garraway, Uri Tabori, James X. Sun, 2017, Genome Medicine.

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

W. Pao, F. Michor, J. Chmielecki, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Recurrent hyperactive ESR 1 fusion proteins in endocrine therapy-resistant breast cancer

B. Leyland-Jones, P. Lucas, G. Frampton, 2018 .

ComprehensiveGenomicProfilingofAdvancedEsophagealSquamous CellCarcinomasandEsophagealAdenocarcinomasRevealsSimilarities and Differences

P. Stephens, R. Yelensky, J. Ross, 2015 .

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

William Pao, Marc Ladanyi, Geoffrey R. Oxnard, 2010, Clinical Cancer Research.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

P. Stephens, J. Ross, S. Ou, 2015, Lung cancer.

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing

P. Stephens, R. Yelensky, S. Ou, 2016, Clinical Cancer Research.

A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms

P. Stephens, O. Basturk, S. Middha, 2018, Modern Pathology.

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion

P. Stephens, V. Miller, Siraj M. Ali, 2015, Journal of Hematology & Oncology.

The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility

W. Muller, P. Siegel, K. Roovers, 2009, Oncogene.

Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.

S. Vowler, J. Barrett, F. Shepherd, 2017 .

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

J. Ahn, M. Ahn, Dong-Wan Kim, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Signaling through ShcA Is Required for Transforming Growth Factor (cid:2) - and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion (cid:1) †

W. Muller, P. Siegel, C. Russo, 2008 .

Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

R. Yelensky, V. Miller, G. Frampton, 2015, Blood Cancer Journal.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

G. Getz, M. Meyerson, James R. Anderson, 2014, Cancer discovery.

Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.

A. Kohlmann, S. Ramalingam, J. Vansteenkiste, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.

P. Stephens, R. Yelensky, W. Pao, 2014, Cancer discovery.

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.

J. Barrett, S. Ramalingam, B. Cho, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations.

P. Stephens, V. Miller, L. Davis, 2015 .

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

William Pao, Juliann Chmielecki, W. Pao, 2010, Nature Reviews Cancer.

Comprehensive molecular profiling of lung adenocarcinoma

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2014, Nature.

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.

Leonard D. Goldstein, R. Gentleman, F. Gnad, 2016, Cell reports.

An ErbB2 splice variant lacking exon 16 drives lung carcinoma

E. Sokol, Philippe P Roux, G. Frampton, 2020, Proceedings of the National Academy of Sciences.

Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Clinical Cancer Research.

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

Chris Sander, Fang Fang, William Pao, 2009, Proceedings of the National Academy of Sciences.

Meningioma transcription factors link cell lineage with systemic metabolic cues

B. Alexander, S. Santagata, L. Sholl, 2018, Neuro-oncology.

Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant

V. Miller, R. Erlich, J. Chmielecki, 2017, Cold Spring Harbor molecular case studies.

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Kai Wang, Doron Lipson, Roman Yelensky, 2015, International journal of cancer.

Whole exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors

Daniel Auclair, Matthew Meyerson, Aaron McKenna, 2013, Nature Genetics.

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

P. Stephens, V. Miller, D. Khaira, 2015, Breast Cancer Research and Treatment.

Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas

C. Brennan, B. Taylor, M. Ladanyi, 2019, Clinical Cancer Research.

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy

P. Stephens, R. Yelensky, B. Leyland-Jones, 2015, OncoTargets and therapy.

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Trevor J Pugh, James X. Sun, P. Stephens, 2017, Cancer research.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

P. Stephens, R. Yelensky, R. Bose, 2016, Cancer.

Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies

R. Yelensky, D. Lipson, V. Miller, 2016 .

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

M. Meyerson, Guangwu Guo, A. Heguy, 2015, Cancer research.

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies

W. Pao, D. Fabrizio, J. Chmielecki, 2017, Genome Medicine.

High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.

Doron Lipson, James Suh, Jie He, 2017, Cancer research.

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study.

J. Barrett, M. Ahn, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.

P. Stephens, G. Manning, Ayşegül Özen, 2016, Cancer cell.

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP 1 , NF 2 , CDKN 2 A , and CUL 1 in Malignant Pleural Mesothelioma

M. Meyerson, Guangwu Guo, A. Heguy, 2014 .

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

P. Stephens, R. Yelensky, S. Ou, 2015, The oncologist.

DNA sequencing of cancer: what have we learned?

Matthew Meyerson, Juliann Chmielecki, M. Meyerson, 2014, Annual review of medicine.

Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204‐PDGFRB fusion in a patient with recurrent T‐ALL and an associated myeloproliferative neoplasm

Annette S. Kim, N. Socci, A. Viale, 2012, Genes, chromosomes & cancer.

Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.

S. Millis, R. Kurzrock, B. Parker, 2017, Cancer research.

A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events

Chandra Sekhar Pedamallu, Angela N. Brooks, Gad Getz, 2014, PloS one.

Comprehensive molecular profiling of lung adenocarcinoma

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2014, Nature.

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

P. Stephens, V. Miller, G. Frampton, 2016, The oncologist.

Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

Alex M. Fichtenholtz, P. Stephens, R. Yelensky, 2015 .

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Zhongming Zhao, N. Socci, A. Viale, 2010, Nucleic acids research.

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Kai Wang, Roman Yelensky, Gary Palmer, 2015, JAMA oncology.

Predictive Biomarkers and Personalized Medicine Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer : Distinct Natural History of Patients with Tumors Harboring the T 790 M Mutation

M. Ladanyi, C. Sima, M. Kris, 2011 .

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

N. Socci, A. Viale, M. Ladanyi, 2011, Science Translational Medicine.

Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.

P. Stephens, R. Yelensky, E. V. Van Allen, 2016, European urology.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

M. Ladanyi, M. Zauderer, R. Yelensky, 2016, The oncologist.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

William Pao, Yumei Pan, Lu Wang, 2012, Proceedings of the National Academy of Sciences.

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

M. Ladanyi, W. Pao, M. Arcila, 2011, Clinical Cancer Research.

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

W. Pao, K. Politi, R. Somwar, 2007, PLoS medicine.

Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression

J. Sicklick, O. Harismendy, M. Kendrick, 2016, Oncotarget.

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Ying Cheng, Y. Ohe, S. Ramalingam, 2023, Nature Communications.

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

Suzanne F. Jones, A. Oza, J. Cragun, 2021, Clinical Cancer Research.

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

J. Barrett, J. Downward, Paul D. Smith, 2021, Nature Communications.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

Adrian V. Lee, B. Leyland-Jones, M. Rosenzweig, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion

P. Stephens, M. Warmuth, P. Zhu, 2017, PloS one.

FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

J. Sicklick, O. Harismendy, James D. Murphy, 2016, Journal of Translational Medicine.

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.

P. Stephens, V. Miller, Siraj M. Ali, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma

James X. Sun, P. Stephens, R. Yelensky, 2016, Oncology.

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.

James X. Sun, R. Yelensky, D. Lipson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

P. Stephens, R. Yelensky, Bahar Yilmazel, 2015, Oncoscience.

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies

P. Stephens, R. Yelensky, D. Lipson, 2014, Journal of Clinical Pathology.

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

P. Stephens, R. Yelensky, D. Lipson, 2014, Journal of Clinical Pathology.

Signaling through ShcA Is Required for Transforming Growth Factor β- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion

W. Muller, P. Siegel, C. Russo, 2008, Molecular and Cellular Biology.

EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib

X. Chen, A. Viale, M. Kris, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Juliann Chmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR-Mutant Non

N. Socci, A. Viale, M. Ladanyi, 2011 .

Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer

W. Pao, J. Chmielecki, 2010, Clinical Cancer Research.

Abstract A23: Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: The Foundation Medicine (FMI) experience

P. Stephens, R. Yelensky, V. Miller, 2014 .

A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy.

J. Sicklick, P. Fanta, J. Chmielecki, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

J. Sicklick, O. Harismendy, James D. Murphy, 2016, Journal of Translational Medicine.

Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid‐type fibromatosis by whole‐exome sequencing and genomic analysis

M. Meyerson, N. Socci, L. Qin, 2015, Genes, chromosomes & cancer.

Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy.

G. Frampton, Siraj M. Ali, N. Palma, 2014 .

Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.

R. Yelensky, S. Ou, D. Lipson, 2014 .

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

P. Stephens, R. Yelensky, D. Lipson, 2016, The oncologist.

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

Philip Smith, J. Riess, B. Cho, 2021, Clinical lung cancer.

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.

Ying Cheng, J. Barrett, S. Ramalingam, 2019, Journal of Clinical Oncology.

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Jie Yang, J. Barrett, M. Ahn, 2023, Nature Communications.

FP16.03 Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

S. Ramalingam, Y. Wu, A. Delmonte, 2021, Journal of Thoracic Oncology.

Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients.

J. Barrett, S. Heo, B. Cho, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation

Suzanne F. Jones, A. Oza, L. Ottesen, 2019, Clinical Trials.

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Suzanne F. Jones, A. Oza, J. Cragun, 2019, Journal of Clinical Oncology.

Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations.

R. Yelensky, T. Choueiri, D. Lipson, 2015 .

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

P. Stephens, V. Miller, G. Palmer, 2014, Clinical Lymphoma, Myeloma & Leukemia.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

James X. Sun, L. Garraway, V. Miller, 2017, Genome Medicine.

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

Suzanne F. Jones, Melissa L. Johnson, J. Sachdev, 2023, Investigational New Drugs.

Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA

B. Chewaskulyong, S. Ramalingam, B. Cho, 2019, Annals of Oncology.

P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy

J. Riess, Paul D. Smith, P. Jewsbury, 2019, Journal of Thoracic Oncology.

Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations.

R. Yelensky, D. Lipson, V. Miller, 2014 .

Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts

Suzanne F. Jones, A. Tinker, A. Oza, 2019, Clinical Trials.

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Suzanne F. Jones, A. Tinker, A. Oza, 2023, Targeted Oncology.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway.

James X. Sun, P. Stephens, R. Yelensky, 2015 .

Abstract 4699: Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test

M. Ladanyi, P. Stephens, R. Yelensky, 2014 .

Abstract LB-178: Genomic profiling of 1239 diverse pediatric cancers identifies novel discoveries across tumors

P. Stephens, D. Lipson, V. Miller, 2016 .

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.

Y. Ohe, S. Ramalingam, B. Cho, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA

A. Kohlmann, S. Ramalingam, J. Vansteenkiste, 2020, Journal of Thoracic Oncology.

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

J. Chmielecki, J. Gray, A. Telaranta-Keerie, 2023, The Journal of Molecular Diagnostics.

t(5;6)(q33-34;q23) CEP85L/PDGFRB

W. Pao, J. Chmielecki, 2013 .

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Nicolai J. Birkbak, Angela E. Leek, P. Van Loo, 2024, Nature communications.

P2.03b-068 The Druggable Mutation Landscape of Lung Adenocarcinoma: Topic: Biomarkers

P. Stephens, V. Miller, G. Frampton, 2017 .

Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer

J. Chmielecki, R. Hartmaier, A. Markovets, 2023, Clinical pharmacology and therapeutics.

3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load

L. Garraway, P. Stephens, R. Yelensky, 2016 .